What is CBG Oil?
Cannabigerol (CBG) is a cannabinoid found cannabis plants, along with more than 120 other identified cannabinoids. The other most notable cannabinoids found in the Cannabis L. Sativa that you may have heard of are THC (phytocannabinoid tetrahydrocannabinol), and CBD oils (Cannabidiol). But just because CBD and THC are more well-known doesn’t mean that CBG products have less beneficial properties.
Cannabigerol (CBG) is a form of CBG cannabigerolic that has been decarboxylated. Cannabigerolic acid is a parent molecule from which other cannabinoids and terpenes are synthesised from and this is why CBG makes up such a minor amount of the Cannabis L. Sativa because as the cannabis plants grow, cannabigerol is converted into other cannabinoids, especially THC. Therefore, in the average fully grown Cannabis L. Sativa, there is only 1% levels of CBG in the plant.
How CBG Oil Is Made?
So, now you know that CBG is the mother of all cannabinoids, you may be wondering how CBG oil is made. We have you covered!
The enzymes in cannabis plants break down the cannabigerolic acid and turn it into CBD and THC. However, many cannabis cultivators have been able to yield more than 1% of CBG from the plant by using selective breeding and crossbreeding, which makes the plant create more Cannabigerol (CBG) rather than converting it into CBD and THC and this is approximately around the two month mark of the flowering cycle.
Then the decarboxylation process starts. This process activates raw cannabis into their enhanced forms. Decarbonating simply entails the removal of the carboxyl molecule. The process allows the cannabinoid to become more potent and produces carbon dioxide gas as a by-product. The cannabigerolic acid converts to Cannabigerol (CBG) after the decarboxylation is finished. Afterwards, the raw cannabis products go through a process called winterisation which is where they dissolve the plant in ethanol and place it in the freezer so the acidic form of CBG can separate more easily separated from the other cannabinoids because they all have different melting points and precipitation points. This then goes towards making CBG products such as CBG oil, CBG tincture, and topicals.
What are the Benefits of CBG Oil?
The discovery of the endocannabinoid system (which you can read more about in our other article) has allowed many studies to occur regarding the interactions between cannabinoids from cannabis plants and the human body. With that ball rolling, scientists also looked into more minor cannabinoids and that’s how CBG products gained more attention when the potential benefits for humans were discovered.
CBG oil still isn’t as thoroughly researched as CBD and THC, but it shows great promise, so let’s look at some potential benefits of CBG oil when dealing with different conditions.
The majority of cannabinoids have the benefit of relieving chronic pain due to their powerful analgesic properties. When CBG oil is taken, it can interact with our CB2 receptors, which are the same receptors in our endocannabinoid system that CBD also interacts with. These pain-regulating CB2 receptors can be given a boost by the CBG oil and aid the endocannabinoid system in reducing your chronic pain.
Although CBD and THC have the most antiemetic properties in testing results, there have been many studies showing that CBG oil can also be effective when treating nausea. Researchers in lab testing have not yet identified how CBG oil manages to achieve this; it is thought to be due to its positive interactions with the endocannabinoid system. Because of this, CBG products may benefit those who suffer from various conditions that cause nauseous symptoms.
Broad spectrum CBG oil has been shown to slow (or stop) the growth of cancer cells in the body. A particular study showed a certain amount of CBG being able to prevent the growth of colorectal cancer cells in mice, therefore, slowing the rate of colon cancer advancement. It was noted that this happened because the CBG isolate was blocking the cannabinoid receptors in the body that can cause cancer growth. Although more research is required, there is amazing potential for CBG products to help with reducing cancer growth along with your other medical advice diagnosis.
CBG oil has proved to have neuroprotective properties in past studies and lab testing. This means spectrum CBG oil has the potential to protect neurons in the brain just as it had in the studies on mice. So it isn’t just Huntington’s Disease that broad spectrum CBG oil can potentially help, but also any other neurodegenerative diseases. Due to CBG oil having the ability to preserve striatal neurons (which is achieved by battling against 3-nitropropionic acid toxicity), it also can help with motor deficits, meaning it could help conditions such as Parkinson’s as well.
Glaucoma and Intraocular Pressure
Glaucoma was actually one of the first conditions treated by cannabis plants in the modern era. This is because after the endocannabinoid system was discovered in lab testing, scientists found many cannabinoid receptors in the eye. CBG oil has been shown to aid in the treatment of intraocular pressure, even more so than THC. This pressure is one of the biggest discomforts that accompany glaucoma, so it can give you that respite from that particular symptom. Read our article for CBD products and CBG products intended to diagnose and treat conditions prominent in over 50s and seniors to discover more benefits.
Researchers’ lab results have found that CBG oil is one of the cannabinoids that have excellent anxiolytic properties and can prevent serotonin and GABA (gamma-aminobutyric acid reuptake) uptake in the brain. Due to CBG oil being able to reduce GABA reuptake, it can elevate your mood, which could help in a variety of mood disorders, such as:
- Post-traumatic stress disorder (PTSD)
- Obsessive-compulsive disorder (OCD)
- Bipolar disorders (also called manic-depressive illness)
- Clinical depression
- Anxiety disorders
Another added benefit of GABA reuptake inhibition caused by CBG oil in the body is that researchers have found muscles relax, which means CBG oil can aid with post-workout muscle recovery (check out our other article about how our muscle repair gel – a CBD topical with CBG – can help improve your workout).
CBG oil has been showing great promise in treating MRSA because of the antibacterial properties it has. The CBG oil can target bacterial cell membranes. Researchers believe this is because CBG as well as other cannabinoids in the Cannabis L. Sativa have evolved to combat pathogens in nature to help the plant survive. If CBG oil is capable of doing this, scientists think that it could be a great antibacterial component in future antibiotics.
Similar to the antibacterial effects, CBG oil has also been shown to reduce inflammation. Several studies have found anti-inflammatory properties in CBG which have aided the mice in the tests. An example of this is the potential for CBG oil to help treat inflammatory bowel disease (IBD) and other gastric inflammation conditions.
Relieving Skin Conditions
Closely connected to the anti-inflammatory effects of CBG oil, it could aid various inflammatory skin conditions. This could include acne, eczema, and psoriasis. CBG oil does this by inhibiting overactive sebaceous glands of the skin, these glands are in charge of secreting sebum (the oil that moisturises and nourishes our skin). Excess sebum production is what causes blockages in the skin pores, leading to conditions such as acne. CBG oil is capable of helping treat these conditions while being suitable for those with sensitive skin. See our Dermal Repair Cream with CBD and CBG if you are looking for something to help with your skin or check out our blog about CBD skin care.
Are There Any Side Effects of CBG Oil?
Other medications usually come with a long list of potential side effects when trying to prevent any disease as well as the diagnose, treat, cure listing, so maybe you are wondering whether CBG oil has any. Studies have found that most people experienced no side effects at all in drug interactions, which is great news! However, everybody is different and our systems can operate in different ways, especially if you have medical conditions. Anything can cause people side effects though, so let’s investigate potential side effects and things that you can do to prevent them so you can experience side effect free CBG oil consumption.
You might already be aware of getting a dry mouth from cannabis, however, it isn’t because of dehydration. There are cannabinoid receptors in the salivary glands, so when you consume CBG oil and introduce more of a particular cannabinoid, it can temporarily affect the production of saliva. This is easily combated by drinking water after having your CBG oil, but the dry mouth will not last long.
Hopefully, it won’t surprise you that this is on the possible side effects list. Another benefit not mentioned above is how CBG oil can be used as a sleep aid, therefore, it is going to make you tired. Those who are using CBG oil to help with their sleep will be glad of this, but what if you aren’t planning to take it for that reason? We suggest you take CBG oil before you go to bed anyway, so if tiredness does strike, it can only be a good thing!
Certain compounds in the Cannabis L. Sativa can suppress or boost the appetite when consumed. It depends on the person in which direction their appetite goes. This only usually happens when high doses of CBG oil is taken and, even then, the swings in appetite should pass when the CBG oil isn’t active in your body.
This is closely connected to appetite changes. Researchers believe that CBG oil’s effects are evaluated by the food and that is what causes people’s weight gain rather than metabolism which they investigated.
How to Use Our CBG Oil
So, if you think CBG oil is suitable for you, how do you use it? The most common method of taking CBG oil (at least, for our oils) is to consume it:
- Squeeze the top of the pipette which draws the CBG oil up into the dropper.
- Drop the CBG oil under the tongue and hold it in your mouth for 30 seconds before swallowing.
So simple! Luckily for you, our CBG oil is tasteless so you don’t have to worry about any unpleasant aftertaste. Now, the dosage depends on your requirements, therefore, the dosage should be built up slowly to get your body used to the substance. However, the usual dosage for our CBG oil is two drops under the tongue daily. For more information, check the directions on our product page. And if you are interested in both CBD and CBG oil, see our article discussing the differences between them here.
We hope you have enjoyed reading this article and have gained a lot of knowledge about CBG oil. Perhaps we have convinced you of all the benefits of CBG oil that could aid you with a particular condition. We also have other products in our CBG range, including CBG with MCT oil, but if oil isn’t for you, there are also CBG and CBD topicals you can purchase. Check out our CBG oil today!
- ‘Potential Medical Uses of Cannabigerol: A Brief Overview’ from the Handbook of Cannabis and Related Pathologies from the Academic Press (2017) by S.Deiana.
- ‘Molecular Pharmacology of Phytocannabinoids’ from Phytocannabinoids (2017) by Sarah E. Turner, Claire M. Williams, Leslie Iversen, and Benjamin J. Whalley.
- ‘An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol’ from Frontiers of Pharmacology (2017) by Paula Morales, Patricia H. Reggio, and Nadine Jagerovic.
- ‘Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes’ from the Journal of Natural Products (2016) by Oier Aizpurua-Olaizola, Umut Soydaner, Ekin Öztürk, Daniele Schibano, Yilmaz Simsir, Patricia Navarro, Nestor Etxebarria, and Aresatz Usobiaga.
- ‘Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa’ from the Federation of European Biochemical Societies (2007) by Futoshi Taura, Supaart Sirikantaramas, Yoshinari Shoyama, Kazuyoshi Yoshikai, Yukihiro Shoyama, and Satoshi Morimoto.
- ‘Production of Δ9-tetrahydrocannabinolic acid from cannabigerolic acid by whole cells of Pichia (Komagataella) pastoris expressing Δ9-tetrahydrocannabinolic acid synthase from Cannabis sativa L’ from Biotechnology Letters (2015) by Bastian Zirpel, Felix Stehle, and Oliver Kayser.
- ‘Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses’ from the International Cannabinoid Research Society (2019) by Melissa M Lewis-Bakker, Yi Yang, Rupali Vyawahare, and Lakshmi P Kotra.
- ‘Cannabinoids and Pain: New Insights From Old Molecules’ from the Frontiers of Pharmacology (2018) by Sonja Vučković, Dragana Srebro, Katarina Savić Vujović, Čedomir Vučetić, and Milica Prostran.
- ‘Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes’ from the Frontiers of Pharmacology (2018) Gemma Navarro, Katia Varani, Irene Reyes-Resina, Verónica Sánchez de Medina, Rafael Rivas-Santisteban, Carolina Sánchez-Carnerero Callado, Fabrizio Vincenzi, Salvatore Casano, Carlos Ferreiro-Vera, Enric I. Canela, Pier Andrea Borea, Xavier Nadal, and Rafael Franco.
- ‘Cannabis‐based medicines for chronic neuropathic pain in adults’ from the Cochrane Database of Systematic Reviews (2018) by Martin Mücke, Tudor Phillips, Lukas Radbruch, Frank Petzke, and Winfried Häuser.
- ‘The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications’ from the Journal of Medicinal Chemistry (2005) by Didier M. Lambert and Christopher J. Fowler.
- ‘Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews’ from Psychopharmacology (2011) by Erin M Rock, Jennifer M Goodwin, Cheryl L Limebeer, Aviva Breuer, Roger G Pertwee, Raphael Mechoulam, and Linda A Parker.
- ‘Effect of Phytocannabinoids on Nausea and Vomiting’ from the Handbook of Cannabis (2014) by Erin M. Rock, Martin A. Sticht, and Linda A. Parker.
- ‘Cannabinoid Effects on Experimental Colorectal Cancer Models Reduce Aberrant Crypt Foci (ACF) and Tumor Volume: A Systematic Review’ from Evidence-Based Complementary and Alternative Medicine (2020) by Eduardo Orrego-González, Luisa Londoño-Tobón, José Ardila-González, Diego Polania-Tovar, Ana Valencia-Cárdenas, and Alberto Velez-Van Meerbeke.
- ‘Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice’ from Neurotherapeutics (2014) by Sara Valdeolivas, Carmen Navarrete, Irene Cantarero, María L. Bellido, Eduardo Muñoz, and Onintza Sagredo.
- ‘In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid’ from the International Journal of Molecular Sciences and Molecular Diversity Preservation International and Multidisciplinary Digital Publishing Institute (2018) by Agnese Gugliandolo, Federica Pollastro, Gianpaolo Grassi, Placido Bramanti, and Emanuela Mazzon.
- ‘A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol’ from the Journal of Ocular Pharmacology and Therapeutics (2009) by Brenda K. Colasanti.
- ‘The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders’ from Current Neuropharmacology (2020) by Sari Goldstein Ferber, Dvora Namdar, Danielle Hen-Shoval, Gilad Eger, Hinanit Koltai, Gal Shoval, Liat Shbiro, and Aron Weller.
- ‘Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review’ from Medicina (2019) by Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti, and John Martin Corkery.
- ‘Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study’ from Depression and Anxiety (2020) by Reilly R Kayser, Margaret Haney, Marissa Raskin, Caroline Arout, and Helen Blair Simpson.
- ‘Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential’ from the Journal of Psychopharmacology (2005) by C H Ashton, P B Moore, P Gallagher, and A H Young.
- ‘Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis’ from The Lancet. Psychiatry (2019) by Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T Tran, Dino Zagic, Wayne D Hall, Michael Farrell, and Louisa Degenhardt.
- ‘Cannabinoids, interoception, and anxiety’ from Pharmacology, Biochemistry, and Behavior (2019) by Allyson K Andrade, Briana Renda, and Jennifer E Murray.
- ‘Antibacterial cannabinoids from Cannabis sativa: a structure-activity study’ from the Journal of Natural Products (2008) by Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, and M Mukhlesur Rahman.
- ‘Uncovering the Hidden Antibiotic Potential of Cannabis’ from ACS Infectious Diseases (2020) by Maya A. Farha, Michael G. DeGroote, Omar M. El-Halfawy, Robert T. Gale, Craig R. MacNair, Lindsey A. Carfrae, Xiong Zhang, Nicholas G. Jentsch, Jakob Magolan, and Eric D. Brown.
- ‘Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease’ from Biochemical Pharmacology (2013) by Francesca Borrelli, Ines Fasolino, Barbara Romano, Raffaele Capasso, Francesco Maiello, Diana Coppola, Pierangelo Orlando, Giovanni Battista, Ester Pagano, Vincenzo Di Marzo, and Angelo A.Izzo.
- ‘An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin’ from the Journal of Drugs in Dermatology (2020) by Jalal Maghfour, Hope R Rietcheck, Chandler W Rundle, Taylor M Runion, Zainab A Jafri, Sam Dercon, Peter Lio, Jon Fernandez, Mayumi Fujita, Robert P Dellavalle, and Helena Yardley.
- ‘An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies’ from the International Cannabinoid Research Society (2017) by Kerstin Iffland and Franjo Grotenhermen.
- ‘Immunohistochemical localization of CB1 receptor in canine salivary glands’ from Veterinary Research Communications (2010) by C Dall’Aglio, F Mercati, L Pascucci, C Boiti, V Pedini, and P Ceccarelli.
- ‘Cannabis, Cannabinoids, and Sleep: a Review of the Literature’ from Current Psychiatry Reports (2017) by Kimberly A Babson, James Sottile, and Danielle Morabito.
- ‘Cannabinoids and appetite: food craving and food pleasure’ from the International Review of Psychiatry (2009) by Tim C Kirkham.